Monitor the September 8, 2026 trial for patent infringement verdict. Lilly's favorable MIL rulings (especially exclusion of internal chats) improve its defense posture, but the case remains unresolved. No immediate trading action warranted.
Price Chart
Executive Summary
The court issued a pretrial order in Nektar Therapeutics v. Eli Lilly & Co, setting a jury trial for September 8, 2026, and resolving motions in limine. Lilly won 5 of its 7 motions, including a key exclusion of Nektar's evidence from Lilly's Microsoft Teams chats (July 2023–Feb 2025), while Nektar won 3 of its 7 motions. This is a procedural ruling that shifts trial leverage modestly in Lilly's favor but does not resolve the underlying patent dispute.
Court Ruling Details
Key Facts
- Jury trial set for September 8, 2026 in Nektar Therapeutics v. Eli Lilly & Co (patent case).
- Lilly won 5 of its 7 motions in limine, including exclusion of Microsoft Teams chats from July 2023–Feb 2025.
- Nektar won 3 of its 7 motions in limine.
- Each side gets 13 hours for witness examinations; trial expected Monday–Thursday.
- No damages, injunction, or liability determination was made — this is a pretrial scheduling and evidence order.
Financial Impact
No financial impact determined — pretrial order with no damages awarded or liability found.
Risk Factors
- Adverse patent infringement verdict at trial could expose Lilly to damages or injunctive relief on a drug product.
- Nektar's granted MILs (Nos. 1, 4, 6) may allow certain evidence that could strengthen its case.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-6cec4005c8-LLY |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 5w ago | Press Release | $1,115.70 $1,179.27 | ▲ +5.70% | ▲ +3.83% | $1,257.03 (+12.67%) |
Sep 8, 2026 5w ago | Court Ruling | $1,123.91 $1,157.49 | ▲ +2.99% | ▲ +1.02% | $1,257.03 (+11.84%) |
Aug 18, 2026 8w ago | Insider Cluster | $1,225.73 $1,137.82 | ▼ −7.17% | ▼ −5.86% | $1,257.03 (+2.55%) |
Aug 11, 2026 9w ago | Insider Cluster | $1,215.02 $1,124.21 | ▼ −7.47% | ▼ −6.42% | $1,257.03 (+3.46%) |
Aug 7, 2026 10w ago | Court Ruling | $1,185.71 $1,149.36 | ▼ −3.07% | ▼ −2.67% | $1,257.03 (+6.01%) |
Aug 5, 2026 10w ago | 8-K | $1,169.86 $1,160.08 | ▼ −0.84% | ▼ −0.23% | $1,257.03 (+7.45%) |
Aug 4, 2026 10w ago | Court Ruling | $1,115.68 $1,160.00 | ▲ +3.97% | ▲ +5.21% | $1,257.03 (+12.67%) |
Jul 31, 2026 11w ago | Court Ruling | $1,148.84 $1,174.61 | ▼ −2.24% | ▲ +0.74% | $1,257.03 (−9.42%) |
Jul 30, 2026 11w ago | Court Ruling | $1,154.97 $1,176.10 | ▲ +1.83% | ▼ −2.14% | $1,257.03 (+8.84%) |
Jul 22, 2026 12w ago | Press Release | $1,163.01 $1,280.34 | ▲ +10.09% | ▲ +7.19% | $1,257.03 (+8.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access